Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Peripheral Blood Stem Cell Transplantation 10Azacitidine 10fludarabine phosphate 8Whole-Body Irradiation 8Cyclosporine 7ruxolitinib 6Mycophenolic Acid 6Busulfan 6Methotrexate 5Cyclophosphamide 5fludarabine 4Tacrolimus 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 3Alemtuzumab 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2eprenetapopt 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Docetaxel 2Cord Blood Stem Cell Transplantation 2tipifarnib 1sonidegib 1rucaparib 1quizartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myeloproliferative Disorders × Interleukin-7 × Clear all
NCT03941769 2024-10-17

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

M.D. Anderson Cancer Center

Phase 1/2 Completed
1 enrolled 5 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡